Prostate Cancer
Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial.
September 10, 2024
Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
September 10, 2024
Predictive factors of hemoglobin drop after robot-assisted radical prostatectomy: a single center prospective study.
September 10, 2024
Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer.
September 9, 2024
Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.
September 9, 2024
Effect of PSMA PET/CT on the Use of Bone Scintigraphy for Prostate Cancer at a University Hospital System.
September 9, 2024
Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients.
September 9, 2024
The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.
September 6, 2024
Comparison of Pathologist and Artificial Intelligence-based Grading for Prediction of Metastatic Outcomes After Radical Prostatectomy.
September 6, 2024
The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions.
September 5, 2024
A Multi-Institutional Study of MR/US Fusion Guided Nanoparticle Directed Focal Therapy for Prostate Ablation.
September 5, 2024
Talazoparib for the treatment of prostate cancer.
September 5, 2024
PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer.
September 5, 2024